EDSA
Edesa Biotech·NASDAQ
--
--(--)
--
--(--)
EDSA fundamentals
Edesa Biotech (EDSA) released its earnings on Dec 12, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.365 (YoY -25.86%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.365
-25.86%
Report date
Dec 12, 2025
EPS
Actual | -1.19 | -1.4 | -1.54 | -1.82 | -1.33 | -2.52 | -2.03 | -2.31 | -2.31 | -2.59 | -1.05 | -0.91 | -0.84 | -0.7 | -0.57 | -0.54 | -0.58 | -0.52 | -0.29 | -0.48 | -0.3 | -0.25 | -0.365 | |||||
Forecast | -1.33 | -1.435 | -1.435 | -1.47 | -2.065 | -2.24 | -2.5667 | -2.8 | -2.5667 | -2.59 | -2.1933 | -1.2367 | -1.1433 | -1.0967 | -0.7033 | -1.21 | -0.6933 | -0.58 | -0.54 | -0.31 | -0.42 | -0.2633 | -0.2667 | |||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +10.53% | +2.44% | -7.32% | -23.81% | +35.59% | -12.50% | +20.91% | +17.50% | +10.00% | 0.00% | +52.13% | +26.42% | +26.53% | +36.17% | +18.95% | +55.37% | +16.34% | +10.34% | +46.30% | -54.84% | +28.57% | +5.05% | -36.86% |
Revenue
Actual | -- | -- | -- | -- | -- | 110.52K | 109.98K | 100.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | 50.00K | 50.00K | 50.00K | 50.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +121.03% | +119.97% | +100.00% | -100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What factors drove the changes in Edesa Biotech's revenue and profit?What is Edesa Biotech's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Edesa Biotech year over year?What were the key takeaways from Edesa Biotech's earnings call?What does Edesa Biotech do and what are its main business segments?Did Edesa Biotech beat or miss consensus estimates last quarter?What were the key takeaways from Edesa Biotech’s earnings call?What guidance did Edesa Biotech's management provide for the next earnings period?
